Skip to content

In the BioHarmony Drug Report Database

Copanlisib

Aliqopa (copanlisib) is a small molecule pharmaceutical. Copanlisib was first approved as Aliqopa on 2017-09-14. It is used to treat follicular lymphoma in the USA. It is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, serine/threonine-protein kinase mTOR, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. Aliqopa's patents are valid until 2032-03-29 (FDA).
Trade Name Aliqopa
Common Name Copanlisib
Indication follicular lymphoma
Drug Class Phosphatidylinositol 3-kinase inhibitors
Copanlisib
Get full access now